David Perry

Dr. David Perry joined Steba biotech in June 2020 to lead the R&D division, overlooking Steba’s research efforts and collaborations, pre-clinical and clinical development, and medical affairs departments, with a current focus on the company’s leading projects in Urology, Lung, and GI.

Prior to joining Steba Dr. Perry served for approximately 25 years in R&D executive roles in both large and small companies, spanning the life science spectrum – medical devices, pharmaceutical small molecules, biotechnological large molecules, combination products, and in-vitro diagnostics. Dr. Perry held position in companies such as Novo Nordisk (Copenhagen), Roche (Palo Alto), Cephalon (London), and Ferring (Copenhagen). Most recently David served as Baxter Bioscience’s global head of clinical and medical affairs, leading their clinical development efforts across all therapy areas.

Dr. Perry is a medical doctor, trained at Haddassah University Hospital, Jerusalem, and holds a B.Med.Sc and M.D. degrees from the Ben Gurion University, Israel.